← All trials
NCT05965687
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2023
- Primary completion
- Aug 30, 2024
- Completion date
- Oct 30, 2024
- First posted
- Jul 28, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 2218
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Nantong UniversityCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversitySponsor investigator
- Changsha Central HospitalCollaborator
- Guizhou Medical UniversityCollaborator
- Jiangxi Provincial People's HospitalCollaborator
- Jining NO.1 People 's HospitalCollaborator
- Jiujiang UniversityCollaborator
- Liaocheng People's HospitalCollaborator
- Linyi People's HospitalCollaborator
- Nanyang Central HospitalCollaborator
- Government of ChinaCollaborator
- People's Hospital of RizhaoCollaborator
- Nanchang UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Xuzhou Medical UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Tianjin Huanhu HospitalCollaborator
- Zhumadian Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.